ASP Health Inc. wins Good Design Award with sample prep platform for cancer diagnostics

We asked 4 of our key experts what are the most important things to get right when developing complex IVD instruments. This is what they said.

Global diagnostics company BluSense Diagnostics has adopted PI’s NeoSync connectivity solution to remotely monitor its fleet of in-market diagnostic instruments.

The demand for at-home patient monitoring and greater personal ownership of healthcare continues to grow, as do the opportunities for emerging players in this space.

At the recent 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, Illinois, I moderated an insightful panel with three industry experts: John Hart, President and CEO of ASP Health; Jay Srinivasan, Chief Strategy Officer at Truvian Sciences and Stuart Elliott, CEO and co-founder of Planet Innovation.  

ASP Health and Planet Innovation have received the Bronze Award in the Testing and Diagnostic Product and Systems category at the 2022 Medical Design Excellent Awards (MDEA) for their innovative, FDA-registered automated sample preparation system.  

Michael Robards recently moderated an insightful panel discussion at BIOMEDevice Silicon Valley on what it’s been like getting in-vitro diagnostic medical devices (IVD) to market over the last few years.

Planet Innovation has launched NeoSync™, a unique, out-of-the box product that connects medical devices to popular Electronic Health Records (EHRs).

When developing connectivity for your point-of-care diagnostic product, there are two main routes – build or buy. How do you know what’s right for you?

PI has partnered with Chicago-based company ASP Health to help them develop and manufacture an innovative sample preparation instrument to enhance cancer diagnostics through more consistent, high quality patient samples.

Planet Innovation is taking another step in providing a safe working environment for on-site staff by introducing voluntary COVID-19 rapid antigen testing at its Australian facility.

Lumos Diagnostics, a PI investee company, has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5 after raising $63 million AUD in an Initial Public Offering (IPO).

As consumers take more ownership over their healthcare, demand is rapidly growing for fast, convenient and accurate point-of-care (POC) tests. But with this migration to POC testing comes a tidal wave of admin that ambulatory clinics are often unprepared for.

As demand for diagnostic and point-of-care (POC) testing grows, new products are coming to life faster than ever. Ben Druce, VP Strategic Design, shares insights from an expert panel discussion he hosted at the MD&M and BIOMEDigital event.

Atmo Biosciences is ramping up manufacture of its third generation gas-sensing capsule at Planet Innovation’s recently opened new medtech manufacturing facility.

Sam Lanyon speaks to the Talking HealthTech podcast about the future of advanced manufacturing and digital health, especially in light of COVID-19.

Experts from Truvian, Blue Ox Healthcare Partners, the University of Chicago and PI discuss the potential impact of real-time point-of-care blood testing.

Silicon Valley start-up LevitasBio has launched the world’s first label-free cell separation platform, the LeviCell™.

Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader.

Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.

PI has partnered with Truvian, a healthcare company at the intersection of diagnostics and consumer technology, to develop a new point-of-care blood testing device to make routine health tests more convenient, affordable and actionable for consumers.

Atmo Biosciences, a digital health business that provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.

From start-ups to established companies, almost everyone in the life sciences and diagnostics industries is playing with digital health in one form or another. But how do you ensure this investment translates into commercial success for your company?

We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new TGA-approved point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.

November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.

Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.

Abbott Molecular’s VIP2000 was recognized for its innovative product design and engineering as a finalist at the prestigious Medical Design Excellence Awards (MDEAs) in New York.

PI has entered into an agreement with Imagion Biosystems, a company dedicated to improving healthcare through the earlier detection of cancer, to develop Imagion’s MagSense instrument technology.

This month’s Association for Molecular Pathology (AMP) 2018 Annual Meeting & Expo focused on the field of precision medicine. Experts from across the molecular diagnostic world gathered in San Antonio, Texas, to exchange knowledge and ideas, with the ultimate aim of creating better patient outcomes.

Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.

Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.

An RMIT University researcher working with PI on technology that can test patients for bleeding or clotting disorders has been awarded more than $650,000 in NHMRC funding.

Clever Culture Systems has collected silver at the prestigious Medical Design Excellence Awards (MDEAs) for its innovative APAS Independence instrument, which Planet Innovation helped develop.

Planet Innovation today announced a partnership with Preora Healthcare Inc., pioneers in the detection of early-stage cancers, to bring to market a series of novel, low-cost, minimally invasive, highly accurate and easy-to-use cancer screening tests.

Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.

Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.